Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J Med Allied Sci. 2020; 10(2): 115-120


Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)

Emmy Palinggi, Muhammad Asykar Palinrungi, Achmad M. Palinrungi, Arifin Seweng, Khoirul Kholis, Syakri Syahrir, Syarif Syarif, Muhammad Faruk.




Abstract

Lower urinary tract symptoms (LUTS) and ureteral-stent-related symp-toms (uSRS) are similar to those of lower urinary tract symptoms caused by benign prostatic hypertrophy (BPH), and complaints about urgency and frequency of urination are the same as in patients with overactive bladder syndrome (OAB). β₃-adrenoceptor agonist (Mirabegron) and anti-muscarinic (Solifenacin) therapies used for LUTS and OAB therapy can also be used to reduce SRS complaints. This study aimed to determine the effectiveness of using Solifenacin as a treatment for uSRS as compared to Mirabegron. This study used a double-blinded experimental design. Samples were taken randomly (consecutive random sampling) from fifty patients with uSRS. Data was collected using the Ureteral Symptoms Score Questionnaire (USSQ) as a measuring instrument. Data was analyzed using the mean, t-Test, and Chi-square tests. P values of

Key words: Mirabegron, Solifenacin, Stent-related symptoms, USSQ






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.